Press Releases
- May 17, 2017Presentations Will Include Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies
- May 16, 2017
- May 1, 2017Directors Douglas Leech, Joseph Maroon and Rodney Piatt to Retire from Board
- Mar 29, 2017
- Mar 20, 2017- TLE400 is a fixed-dose combination containing Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg -
- Mar 13, 2017
- Mar 10, 2017
- Mar 1, 2017Fourth Quarter Total Revenues Increase 31% and Full Year 2016 Total Revenues Increase 18%
- Feb 16, 2017Second Successful BLA Filing of the Partnership in the U.S.
- Jan 11, 2017If Approved, MYL-1401O Has Potential To Be the First Biosimilar Trastuzumab in the U.S.
- Dec 29, 2016
